Monoclonal IgM Antibodies Targeting Candida albicans Hyr1 Provide Cross-Kingdom Protection Against Gram-Negative Bacteria
Recent years have seen an unprecedented rise in the incidence of multidrug-resistant (MDR) Gram-negative bacteria (GNBs) such as Acinetobacter and Klebsiella species. In view of the shortage of novel drugs in the pipeline, alternative strategies to prevent, and treat infections by GNBs are urgently...
Main Authors: | Eman G. Youssef, Lina Zhang, Sondus Alkhazraji, Teclegiorgis Gebremariam, Shakti Singh, Nannette Y. Yount, Michael R. Yeaman, Priya Uppuluri, Ashraf S. Ibrahim |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00076/full |
Similar Items
-
The Hyr1 protein from the fungus Candida albicans is a cross kingdom immunotherapeutic target for Acinetobacter bacterial infection.
by: Priya Uppuluri, et al.
Published: (2018-05-01) -
Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis
by: Priya Uppuluri, et al.
Published: (2018-06-01) -
GRP78 and Integrins Play Different Roles in Host Cell Invasion during Mucormycosis
by: Abdullah Alqarihi, et al.
Published: (2020-06-01) -
Discovery of Novel Type II Bacteriocins Using a New High-Dimensional Bioinformatic Algorithm
by: Nannette Y. Yount, et al.
Published: (2020-09-01) -
Evaluation of Sex Differences in Murine Diabetic Ketoacidosis and Neutropenic Models of Invasive Mucormycosis
by: Teclegiorgis Gebremariam, et al.
Published: (2021-04-01)